Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259710 | 0.93 | ADORA1 (0.70) | ADORA1ADORA2AMAPK1MAPTALDH1A1 | |
| SCHEMBL4253955 | 0.91 | ADORA1 (0.69) | ADORA1ADORA2AMAPK1MAPTALDH1A1 | |
| SCHEMBL4252331 | 0.88 | ADORA1 (0.71) | ADORA1ADORA2AADORA3 | |
| SCHEMBL4261130 | 0.86 | ADORA1 (0.76) | ADORA1ADORA2AALDH1A1PDE5AADORA3 | |
| SCHEMBL4250469 | 0.85 | ADORA1 (0.70) | ADORA1ADORA2AADORA3 | |
| SCHEMBL8357605 | 0.84 | ADORA1 (0.80) | ADORA1ADORA2AMAPTALDH1A1LMNA | |
| SCHEMBL4258069 | 0.84 | ADORA1 (0.72) | ADORA1ADORA2APDE5AADORA3 | |
| SCHEMBL4253074 | 0.84 | ADORA1 (1.00) | ADORA1ADORA2AMAPTALDH1A1LMNA | |
| SCHEMBL4252147 | 0.83 | ADORA1 (0.71) | ADORA1ADORA2AADORA3 | |
| SCHEMBL4253393 | 0.83 | ADORA1 (0.71) | ADORA1ADORA2APDE5AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598252-B2 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-2011499-A2 | Pyrrolo[2,3d]Pyrimidine compositions and their use | OSI Pharmaceuticals, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1731520-A1 | Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3 | OSI Pharmaceuticals, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1246623-B1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARM INC (US) | 2006-08-09 | — | — | EP | disclosed |
| US-6878716-B1 | Compounds specific to adenosine A1 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050043332-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-6680322-B2 | FOR THERAPY OF ASTHMA, ALLERGIC RHINITIS, RESPIRATORY SYSTEM DISORDERS | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6673802-B2 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | OSI PHARMACEUTICALS, INC. | 2004-01-06 | — | — | US | disclosed |
| US-6664252-B2 | (6-aryl-pyrrolo(2,3-d)pyrimidin-4-yl)amine derivatives; treating Parkinson's disease and diseases associated with locomotor activity, vasodilation, platelet inhibition, neutrophil superoxide generation, cognitive disorders, etc. | OSI PHARMACEUTICALS, INC. | 2003-12-16 | — | — | US | disclosed |
| US-20030073708-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030045536-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-02-20 | — | — | US | disclosed |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| US-20020058667-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-05-16 | — | — | US | disclosed |
| US-20020028782-A1 | Pyrrolo [2, 3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073708-A1 | Compounds specific to adenosine A3 receptor and uses thereof | ADORA3, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885MAPK1 3925/4885 |
| US-20020058667-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885MAPK1 1892/4885 |
| US-20030045536-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885MAPK1 1892/4885 |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885MAPK1 3484/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA2A 2/4885MAPK1 2298/4885 |
| US-20050043332-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | TYMP, UMPS, ADORA3 | ADORA1 38/4885ADORA2A 7/4885MAPK1 3835/4885 |
| US-20020028782-A1 | Pyrrolo [2, 3d] pyrimidine compositions and their use | TYMP, UMPS, ADORA3 | ADORA1 38/4885ADORA2A 7/4885MAPK1 3835/4885 |
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | ADORA2A, ADORA2B, ADORA3 | ADORA1 4/4885ADORA2A 1/4885MAPK1 3840/4885 |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | ADORA3, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885MAPK1 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.